Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Current Leases (2016 - 2025)

Adma Biologics (ADMA) has disclosed Current Leases for 14 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases fell 10.02% year-over-year to $1.1 million, compared with a TTM value of $1.1 million through Dec 2025, down 10.02%, and an annual FY2025 reading of $1.1 million, down 10.02% over the prior year.
  • Current Leases was $1.1 million for Q4 2025 at Adma Biologics, down from $1.3 million in the prior quarter.
  • Across five years, Current Leases topped out at $1.3 million in Q3 2025 and bottomed at $317910.0 in Q1 2021.
  • Average Current Leases over 5 years is $898699.1, with a median of $981213.5 recorded in 2023.
  • The sharpest move saw Current Leases surged 105.72% in 2022, then fell 10.02% in 2025.
  • Year by year, Current Leases stood at $591084.0 in 2021, then surged by 53.11% to $905000.0 in 2022, then rose by 15.47% to $1.0 million in 2023, then increased by 16.56% to $1.2 million in 2024, then fell by 10.02% to $1.1 million in 2025.
  • Business Quant data shows Current Leases for ADMA at $1.1 million in Q4 2025, $1.3 million in Q3 2025, and $1.1 million in Q2 2025.